Tirzepatide Cost 2026: Brand vs Compounded vs Telehealth

In 2026, Eli Lilly publishes a wholesale acquisition cost of $1,079.77 per pack of four Mounjaro pens and no list price at all for Zepbound, but the Zepbound self-pay ladder Lilly does publish per dose starts far below that — a regular $299/month at 2.5 mg, $399/month at 5 mg, $499/month at 7.5 mg and $699/month each at 10 mg, 12.5 mg and 15 mg for the single-patient-use KwikPen, with a purchase offer that holds the four highest doses at $449 a month; at 2.5 and 5 mg the regular price is already lower. Those six regular prices are the six Zepbound self-pay rows in our price-per-mg index; the single-dose vial ladder Lilly announced on December 1, 2025 is no longer an index row, because no reachable Lilly page prices a vial by dose. Compounded tirzepatide is now sharply restricted after the FDA declared the shortage resolved. This guide compares every pricing pathway.

Tirzepatide cost at a glance

• Brand list price (Zepbound): not published by Lilly
• Brand wholesale acquisition cost (Mounjaro): $1,079.77 per pack of 4 pens, all strengths (Lilly WAC disclosure)
• Zepbound KwikPen self-pay, regular price: $299/month at 2.5 mg; $399/month at 5 mg; $499/month at 7.5 mg; $699/month each at 10 mg, 12.5 mg and 15 mg (Lilly) — the six rungs our price-per-mg index carries
• Zepbound KwikPen purchase offer: $449/month at 7.5, 10, 12.5 and 15 mg only — at 2.5 and 5 mg the regular price is already lower; automatic on a first purchase, held only if each refill is bought within 45 days, and the card that carries it expires December 31, 2026
• Zepbound single-dose vials: Lilly announced a $299/$399/$449 vial ladder on December 1, 2025, but no reachable Lilly page prices a vial by dose today, so the index carries no vial row
• Commercial insurance with coverage: as low as $25/month via Lilly savings card
• Medicare GLP-1 Bridge (from July 1, 2026): $50 copay per 30-day supply for eligible beneficiaries (Zepbound KwikPen only)
• Compounded tirzepatide: now restricted — broad 503A/503B compounding ended in 2025 after the FDA declared the shortage resolved
• Telehealth compounded pricing (where still legally available): roughly $125–$400/month, narrowing fast under FDA enforcement

What is tirzepatide and why does its cost vary so much?

Tirzepatide is a once-weekly injectable peptide that activates two incretin receptors, GIP and GLP-1. Eli Lilly sells it under two brand names: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management. Both contain the same active molecule, but they are priced, covered, and discounted differently.

Tirzepatide's cost varies for three reasons. First, the channel matters: a retail pharmacy fill, a manufacturer self-pay pen, and an insurance copay are three different prices for the same drug. Second, insurance status swings the out-of-pocket figure from roughly $25 to well over $1,000. Third, the legal landscape for compounded copies changed in 2025–2026, removing what had been the cheapest pathway for many people. In a 72-week head-to-head trial, tirzepatide produced 20.2% mean body-weight reduction versus 13.7% for semaglutide, which helps explain sustained demand and limited price competition (Aronne et al., 2025, N Engl J Med).

For a deeper look at the molecule itself, see our tirzepatide complete guide. Because the Mounjaro pack price is identical across strengths, tirzepatide is much cheaper per milligram than semaglutide — our price-per-mg index shows the computed figures side by side. For how it stacks up against the other leading incretin, see semaglutide vs tirzepatide.

How much does brand-name tirzepatide cost in 2026?

Brand-name tirzepatide carries a high list price, but very few people pay the full list. Here is how the brand channel breaks down.

The list price is the manufacturer's pre-discount sticker. Most insured patients never pay it. With a commercial plan that covers tirzepatide, Lilly's savings card can bring the monthly cost to as little as $25. With a commercial plan that does not cover it, a separate savings tier can lower a fill to roughly $499. People with government insurance — Medicare, Medicaid, TRICARE, VA — generally cannot use manufacturer savings cards.

A meaningful change for 2026: the Medicare GLP-1 Bridge, a temporary CMS demonstration, will give eligible Part D beneficiaries access to certain GLP-1 weight medications — including the Zepbound KwikPen — for a $50 copay per 30-day supply, running July 1, 2026 through December 31, 2027 (CMS, 2026). The $50 copay does not count toward the Part D deductible or out-of-pocket cap.

How much does self-pay Zepbound cost?

Lilly's Zepbound KwikPen Self-Pay Savings Card is the most affordable regulated, brand-authentic tirzepatide pathway in 2026 for cash-pay patients. Lilly offers it at LillyDirect Pharmacy — its own direct-to-patient pharmacy — and at other participating pharmacies, so this is not a single-channel price. A valid prescription is still required.

The ladder Lilly publishes per dose is for the single-patient-use KwikPen, and those six regular prices are the six Zepbound self-pay rows in our price-per-mg index:

• 2.5 mg: $299/month
• 5 mg: $399/month
• 7.5 mg: $499/month
• 10 mg: $699/month
• 12.5 mg: $699/month
• 15 mg: $699/month

Lilly defines a month on this ladder as "28-days and up to 1 single-patient-use KwikPen" — exactly four weekly doses (Lilly, retrieved September 30, 2026). A purchase offer lowers the 7.5 mg, 10 mg, 12.5 mg and 15 mg doses to $449/month — Lilly states it is "valid for 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses" only, and at 2.5 mg and 5 mg the regular price is already below $449. It applies automatically on a first purchase and is held only if each refill is bought within 45 days of the prior delivery, and the card that carries it expires December 31, 2026. The index carries the regular price rather than the offer, so an expiring promotion cannot leave a stale figure behind — the same treatment the Wegovy self-pay row gets for its $199 introductory tier.

One rung needs a caveat. Lilly states that 2.5 mg is a starting dose and is not approved as a maintenance dose, so a cost per milligram computed from it is the cost of a titration month rather than of ongoing treatment. The index carries that row but flags it as not comparable for exactly that reason.

This ladder is not the single-dose Pen, for which Lilly publishes no price at all, and not the single-dose vial. On December 1, 2025 Lilly announced a vial ladder — the 2.5 mg starter dose to $299/month (down from $349), the 5 mg dose to $399/month (down from $499), and the 7.5 mg through 15 mg doses to $449/month under the Self Pay Journey Program from February 23, 2026, against regular non-program prices of $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg (Eli Lilly and Company, 2025). That is reported here as what Lilly announced on that date, not as a current price: the investor release carrying it returns an error to automated checks, no reachable Lilly page prices a vial by dose, and the index therefore carries no vial row at all. Lilly does footnote that the $299 month applies to the Zepbound KwikPen or vial, not to the Zepbound single-dose Pen.

All of these are brand-name tirzepatide — not compounded copies. Confirm the current price for your own dose and presentation with Lilly or your pharmacy before planning around it.

How much does compounded tirzepatide cost, and is it still available?

Compounded tirzepatide was historically the cheapest route, often $150–$400/month through telehealth. That pathway is now sharply restricted, and price is no longer the main consideration — legality is.

Compounding pharmacies were permitted to make copies of tirzepatide only while it sat on the FDA drug shortage list. The FDA determined the tirzepatide shortage was resolved and then ended enforcement discretion: for state-licensed 503A pharmacies as of February 18, 2025, and for 503B outsourcing facilities as of March 19, 2025 (FDA, 2025). A federal district court declined to block the FDA's position in 2025, and the Fifth Circuit affirmed on August 27, 2026 (opinion revised September 1, 2026) in Outsourcing Facilities Ass'n v. FDA, No. 25-10758, with a companion tirzepatide case decided the same day (opinion).

The restriction tightened further in 2026. On April 30, 2026, the FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list, stating it had not identified a clinical need for outsourcing facilities to compound them from bulk drug substances (FDA, 2026). Separately, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026 to evaluate a set of unapproved research peptides for the 503A affirmative list — a process distinct from the approved GLP-1 drugs, but a signal of how actively the agency is policing the compounded-peptide space (FDA, 2026). The GLP-1 drugs were not among the seven peptides reviewed; see full regulatory status.

What this means for cost in 2026:

• A narrow 503A exception can still apply for an individual patient with a documented, prescriber-justified clinical need (for example, an allergy to an inactive ingredient) — not for cost savings alone.
• Where compounded tirzepatide is still lawfully dispensed, telehealth pricing has ranged roughly $125–$400/month, but availability is contracting as enforcement expands and several large telehealth brands have exited compounding.
• Compounded products are not FDA-approved, are not reviewed for the same manufacturing standards as brand tirzepatide, and have been the subject of FDA warning letters. Quality, dosing accuracy, and sourcing vary by pharmacy.

Before considering any compounded or non-standard source, review our peptide sourcing guide and consult your healthcare provider. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Brand vs compounded vs telehealth: which is cheapest in 2026?

There is no single "cheapest" answer — it depends on insurance and eligibility. A rough ranking for a typical patient:

1. Commercial insurance that covers tirzepatide → as low as $25/month (savings card). Cheapest when available.
2. Medicare GLP-1 Bridge (eligible beneficiaries, from July 1, 2026) → $50/month for the Zepbound KwikPen.
3. Zepbound KwikPen self-pay → a regular $299/month at 2.5 mg, $399/month at 5 mg, $499/month at 7.5 mg and $699/month at 10–15 mg, or $449/month at 7.5–15 mg under the purchase offer, which rides on a card that expires December 31, 2026; our price-per-mg index carries the six regular prices. Best regulated cash-pay route.
4. Compounded via 503A (narrow eligibility) → variable, historically $125–$400/month, but legally restricted and quality-variable.
5. Brand list price, fully uninsured, no program → ~$1,000+/month. The figure to avoid.

The headline shift since 2024 is that the gap between brand and compounded has narrowed: brand self-pay now runs from a regular $299/month at the starting dose to $699/month at the top maintenance doses — or $449/month at the four highest doses while the purchase offer runs — while compounded access shrank. For many cash-pay patients, the regulated Lilly self-pay channel is now both safer and competitively priced. Decisions about therapy, dose, and source should be made with a licensed clinician. Consult your healthcare provider before starting any peptide protocol.

Keep reading: browse the full Sourcing library, or start from our Fat Loss hub to see how this piece fits the wider picture. For the two leading GLP-1 options head to head, see tirzepatide vs semaglutide.

Frequently asked questions

Q: How much does tirzepatide cost per month in 2026? A: It depends entirely on your pathway. With commercial insurance that covers it, tirzepatide can cost as little as $25/month using Eli Lilly's savings card. Without insurance, Lilly's published self-pay ladder for the Zepbound single-patient-use KwikPen runs $299/month at 2.5 mg, $399/month at 5 mg, $499/month at 7.5 mg and $699/month each at 10 mg, 12.5 mg and 15 mg, and a purchase offer holds the 7.5, 10, 12.5 and 15 mg doses at $449/month if each refill is bought within 45 days — at 2.5 and 5 mg the regular price is already lower, and the card that carries the offer expires December 31, 2026. Lilly's published wholesale acquisition cost for Mounjaro is $1,079.77 per pack of four pens; it publishes no Zepbound list price. Few people pay either figure. Eligible Medicare beneficiaries may pay $50/month through the GLP-1 Bridge starting July 1, 2026. Costs change frequently; confirm current pricing with the pharmacy and your provider.

Q: Is Zepbound or Mounjaro cheaper? A: Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and Lilly's published wholesale acquisition cost for Mounjaro is $1,079.77 per pack of four pens, with no Zepbound list price published. The practical cost difference comes from coverage and discounts, not the drug. Mounjaro is approved for type 2 diabetes and is more often covered by insurance for that indication; Zepbound is approved for weight management and has a published Lilly self-pay ladder that starts at $299/month for the 2.5 mg KwikPen — a starting dose Lilly says is not approved as a maintenance dose — and reaches $699/month at the top three doses. Which is cheaper for you depends on your diagnosis, insurance, and eligibility for manufacturer programs. Discuss the right product with your healthcare provider.

Q: Why is compounded tirzepatide so much harder to get in 2026? A: Compounding pharmacies could legally copy tirzepatide only while it was on the FDA drug shortage list. The FDA declared the shortage resolved and ended enforcement discretion for 503A pharmacies on February 18, 2025 and for 503B outsourcing facilities on March 19, 2025. In April 2026 the FDA also proposed excluding tirzepatide from the 503B bulks list. A narrow 503A exception remains for individual patients with a documented clinical need, but not for cost savings. As a result, broad, low-cost compounded access has largely ended. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: Does insurance cover tirzepatide for weight loss? A: Coverage varies widely. Many commercial plans cover Mounjaro for type 2 diabetes but exclude weight-loss use; some now cover Zepbound for obesity. With a covered commercial plan, the Lilly savings card can lower the cost to about $25/month. Starting July 1, 2026, the temporary Medicare GLP-1 Bridge offers eligible Part D beneficiaries the Zepbound KwikPen for a $50 copay. People with Medicare, Medicaid, TRICARE, or VA benefits generally cannot use manufacturer savings cards. Check your specific plan's formulary and prior-authorization rules with your provider.

Q: Is self-pay Zepbound real, FDA-approved tirzepatide? A: Yes. Zepbound bought with Lilly's self-pay savings card — at LillyDirect Pharmacy or another participating pharmacy — is brand-name tirzepatide from Eli Lilly, the manufacturer, and is FDA-approved, not a compounded copy. The ladder Lilly publishes per dose is for the single-patient-use KwikPen, which Lilly distinguishes from the single-dose Pen: the footnote states that the $299 month applies to the KwikPen or vial, not to the single-dose Pen. A valid prescription is required, and the $449 purchase offer applies only at 7.5, 10, 12.5 and 15 mg, depends on buying each refill within 45 days of the prior delivery, and rides on a card that expires December 31, 2026. Confirm current terms and whether self-administration is appropriate for you with your healthcare provider.

Q: Will tirzepatide get cheaper after it goes generic? A: Not soon. Tirzepatide is under patent protection, and no generic is available in 2026, so meaningful generic price competition is years away. Near-term cost relief is coming instead from manufacturer programs (Lilly's published self-pay KwikPen ladder, savings cards) and the temporary Medicare GLP-1 Bridge rather than generics. Compounded copies are not generics and are now legally restricted. For the latest pricing, check LillyDirect and your insurer directly, and discuss options with your provider.

References

1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID: 40353578. DOI: 10.1056/NEJMoa2416394.
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved; 503A enforcement discretion ended Feb 18, 2025; 503B ended Mar 19, 2025). FDA Drug Alerts and Statements, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
3. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA Press Announcements, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
4. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
5. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge ($50 copay per 30-day supply; July 1, 2026 – December 31, 2027). CMS, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
6. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials (2.5 mg $299; 5 mg $399; 7.5–15 mg $449 under the Self Pay Journey Program, effective Feb 23, 2026; non-program prices $499 for 7.5 mg and $699 for 10/12.5/15 mg). Lilly Investor News, December 1, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials
7. Eli Lilly and Company. Zepbound coverage and savings — Zepbound KwikPen Self-Pay Savings Card Program and Purchase Offer Terms (regular 1-month self-pay prices $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg; $449 purchase offer, 45-day refill condition, on a card that expires December 31, 2026). Retrieved September 30, 2026. https://zepbound.lilly.com/coverage-savings